LONDON (Alliance News) - Sareum Holdings PLC on Monday said it noted its licensee Sierra Oncology's webcast discussing clinical findings and possible next steps for SRA737, its oral checkpoint kinase 1 inhibitor.
Meanwhile, positive preliminary clinical data from two first-in-human phase 1/2 studies of SRA737, as monotherapy and as low dose gemcitabine, were presented on Saturday last week.
The two phase 1/2 signal-seeking clinical trials were successful in establishing safety and proof-of-concept activity in multiple cancer indications, such as identifying genetic contexts that sensitise tumours to SRA737, Sareum said.
Also, a "very promising" signal was observed in anogenital cancer, which represents a tractable opportunity to potentially pursue trials leading to market registration filings given its unmet medical need.
Looking forward, Sierra said it intends to evaluate further the clinical data in the context of its emerging pipeline, noting that a phase 2 registration trial for SRA737+LDG in anogenital cancer would cost an estimated USD10 million.
"It seems clear that, with proof-of-concept established, there are multiple opportunities for the ongoing development of this exciting prospect, particularly in combination with other therapeutic approaches," said Sareum Chief Executive Tim Mitchell.
"The success of the trials and the exciting future development opportunities discussed increases the likelihood of further milestone payments being received and we look forward to further development updates in due course," Mitchell added.
Sareum shares closed 4.2% higher on Monday at 0.62 pence each.
Sareum (SAR)